The interesting development for this company is that David Williams has changed the focus from being an early stage cancer test developer in to a research platform company.

The EXO-NET technology which allows the collection of exosomes is key to isolating the biomarkers associated with the specific cancer.

The company is providing the technology to academics and pharma companies with a view to expanding sales and royalties on innovative tests and therapeutics.

Early stage but plenty of potential. SP is well down from my buy in RL.

Hi @laoshi

I believe they still have their own exsome products they are developing. But yes, the EXO_NET is designed for research...and by using it, the researcher agrees to sharing any future revenue if they develop a successful product.

But IIQ def has their own exosome products.

I'm hoping we start to see/hear about the progress of the commercialisation of the SubB2M-BC (Breast Cancer) monitoring product soon. We have lots of cash for a decent runway, but if we can start to being in some money.....it really starts to allow them to build and scale.

I note that for once, IIQ has delivered to a timeline! I'm guessing this is partly due to DW.

Today's announcement is classic DW "WEAPONISING EXOSOMES FOR BREAST CANCER TREATMENT".

CSO Prof Gregory Rice said: “INOVIQ’s team has delivered significant progress in the complex task of successfully developing a robust and reproducible CAR-exosome production process. The results obtained in this POC are impressive, comparing very favourably with previously published data. I believe that further enhancement of cancer killing activity is realistically achievable. INOVIQ has established its CAR-exosome platform and is well placed to deliver in vivo data on the anti-tumour efficacy of its CAR-NK-exosome breast cancer therapeutic in CY25.”